Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06478186 · ClinicalTrials.gov registry record · Phase 4
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
A Phase 4 study of Diabetes Mellitus, Type 2 and Osteoarthritis, Knee, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06478186 is a Phase 4 study of Diabetes Mellitus, Type 2 and Osteoarthritis, Knee that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 120 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06478186, a Phase 4 study of Diabetes Mellitus, Type 2 and Osteoarthritis, Knee, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2 Randomized Study to Evaluate the Effects of triamcinolone acetonide extended-release (TA-ER; Zilretta) vs. triamcinolone acetonide immediate-release (TA-IR; Kenalog) on Blood Glucose Levels in Diabetic Subjects with Knee Osteoarthritis. Subjects should have Type 2 Diabetes Mellitus (T2DM) with HbA1C ≤9 that is managed without insulin and have been diagnosed with symptomatic unilateral or bilateral osteoarthritis (OA) of the knee, based on clinical and radiological criteria (if bilateral, then a target knee will be selected).Total study duration for individual subject will be about 4 months, which includes 3 weeks of Screening period, 10 days of pretreatment phase, treatment day, and 12 weeks of post-treatment period.
Conditions Studied
Interventions
- DRUG triamcinolone acetonide extended-release injectable suspension; TCA-ER
- DRUG Triamcinolone Acetonide- Immediate Release;TCA-IR
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2026-10-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06478186
The ClinicalTrials.gov registry entry for NCT06478186 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which triamcinolone acetonide extended-release injectable suspension; TCA-ER is the first listed.
NCT06478186 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06478186 about?
NCT06478186 is a clinical study titled "Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes". A Phase 2 Randomized Study to Evaluate the Effects of triamcinolone acetonide extended-release (TA-ER; Zilretta) vs. triamcinolone acetonide immediate-release (TA-IR; Kenalog) on Blood Glucose Levels in Diabetic Subjects with Knee Osteoarthritis. Subjects should have Type 2 Diabetes Mellitus (T2DM) ...
What is the current status of trial NCT06478186?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-08-16. Estimated completion is 2026-10-16.
What conditions does trial NCT06478186 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Osteoarthritis, Knee.
What interventions are being tested in trial NCT06478186?
The interventions under investigation include: triamcinolone acetonide extended-release injectable suspension; TCA-ER (DRUG), Triamcinolone Acetonide- Immediate Release;TCA-IR (DRUG).
Who is sponsoring clinical trial NCT06478186?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06478186 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
-
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.